Latest / The Needle and the Narrative / Dr. Quang Pham
Transcript
- 0:03Speaker 1: Welcome to the Needle and the Narrative, an ever changing
- 0:06Speaker 1: podcast rooted in a desire to change the way society
- 0:09Speaker 1: treats people who use drugs. This podcast is hosted by
- 0:13Speaker 1: Challenges Inc. Sc, a syringe service program operating in South Carolina.
- 0:18Speaker 1: We will be sitting down with SSP staff, participants, other
- 0:21Speaker 1: harm reductionists, and community partners to learn more about harm
- 0:25Speaker 1: reduction and drug user health. If you'd like to help
- 0:28Speaker 1: the cause, follow Challenges Inc. On social media like review
- 0:31Speaker 1: and share this podcast and check us out online at
- 0:34Speaker 1: Challengesinc Dot org to learn more. It really helps us out.
- 0:39Speaker 1: Thanks are you trying to engage more people with your
- 0:42Speaker 1: outreach program. People who prefer to smoke their drugs can
- 0:45Speaker 1: benefit from safer use supplies as well. Try smoke Works
- 0:48Speaker 1: for the finest glassware around, from stems and oil burners
- 0:52Speaker 1: to other safer smoking supplies. Smoke Works removes barriers and
- 0:56Speaker 1: allows you, the harm reductionists, to meet people where they are.
- 1:01Speaker 1: No pipes, no budget, no problem with the new material
- 1:05Speaker 1: aid program. Smoke Works provides free pipes to any harm reduction,
- 1:09Speaker 1: HIV or overdose prevention org that can't afford or can't
- 1:13Speaker 1: purchase these supplies on their own. Visit smokeworks dot org
- 1:17Speaker 1: to learn more. So I wanted I wanted to talk
- 1:20Speaker 1: about like the I mean, I guess it goes with
- 1:25Speaker 1: the low barrier stuff. But you know, you came to
- 1:29Speaker 1: our mobile unit and created a pathway for people to
- 1:35Speaker 1: have faster access into care than what currently existed. So
- 1:46Speaker 1: I don't know what there is to talk about that.
- 1:47Speaker 1: But maybe it's just a pad on the back. But
- 1:51Speaker 1: that's not typical, right, Like you don't see the doctor
- 1:56Speaker 1: of the clinic like dry I have to a mobile
- 2:02Speaker 1: unit or wherever and try to create their own fast
- 2:06Speaker 1: track through the system. I mean, that was huge for us.
- 2:11Speaker 1: I know that. You know, the people who work on
- 2:13Speaker 1: our mobile unit were like so blown away by that.
- 2:18Speaker 1: And you know, I don't know how many clients they
- 2:22Speaker 1: they referred successfully, but I know just the idea and
- 2:27Speaker 1: the thought and the sentiment alone meant a lot to
- 2:29Speaker 1: them that a doctor would go out of their way
- 2:33Speaker 1: to create some sort of program. I guess maybe if
- 2:35Speaker 1: nothing else, My question is just like why do you
- 2:40Speaker 1: think we don't see more of that from treating physicians?
- 2:45Speaker 1: You know, I think from the layman's side, it's easy
- 2:50Speaker 1: to believe that all physicians got into medicine because they
- 2:54Speaker 1: care about people or care about treating people. So for us,
- 2:59Speaker 1: you would think that would be like the default, but
- 3:02Speaker 1: it doesn't seem to be that way, you know.
- 3:05Speaker 2: I think we all did go into medicine to help people.
- 3:09Speaker 2: I think somewhere along the lines with the numbers of
- 3:13Speaker 2: you know, when people focus on productivity, how many patients
- 3:17Speaker 2: you have to see per day, I think they start
- 3:21Speaker 2: getting overwhelmed and they start getting burnt out. So on average,
- 3:26Speaker 2: I think a patient who abuses substances tend to be
- 3:30Speaker 2: much more complex than your average person. So I think
- 3:34Speaker 2: the concern there is it takes longer to do the
- 3:36Speaker 2: full evaluation. I think at the main recovery clinic, I
- 3:41Speaker 2: think even new appointment is like an hour. Whereas for me,
- 3:47Speaker 2: I realized that you can do. You can kind of
- 3:50Speaker 2: triosh you do what's important first. So for me when
- 3:53Speaker 2: I see them, instead of asking what substances have you
- 3:57Speaker 2: used in the last five years, ten years, I kind
- 4:01Speaker 2: of trioj you as to are you suicidal? Are you homicidal?
- 4:05Speaker 2: Are you seeing things that are not there? You know,
- 4:07Speaker 2: basically like psychotic system or symptoms and basically when what
- 4:10Speaker 2: you used the last week, you know, and then that
- 4:13Speaker 2: kind of expedite things for me so I can immediately
- 4:17Speaker 2: see and evaluate and treat a patient within you know,
- 4:20Speaker 2: ten to fifteen minutes. So I was able to kind
- 4:23Speaker 2: of double book triple book patients on my schedule for
- 4:26Speaker 2: the first of appointment. So like a quick and dirty
- 4:28Speaker 2: kind of deal. Just make sure that they're an overdose, you know,
- 4:30Speaker 2: give them the nart can, and then use subsequent physicists
- 4:33Speaker 2: to kind of dig in further and further into the history.
- 4:35Speaker 1: Right.
- 4:36Speaker 2: Yeah, So that's why.
- 4:37Speaker 1: So you've kind of created your own streamlined protocol for
- 4:43Speaker 1: like what's important, what's the information I need right now,
- 4:47Speaker 1: and then what are some things I can get at
- 4:48Speaker 1: other appointments.
- 4:49Speaker 2: Right So because of that, I'm not worried that they're
- 4:52Speaker 2: going to take me an hour. Some of them still
- 4:54Speaker 2: take me like thirty for the minute, depending on how
- 4:57Speaker 2: in what kind of like medical condition they are. If
- 5:00Speaker 2: someone is actively suicidal, I need to make sure that
- 5:02Speaker 2: you know, nothing bad is gonna happen in the next
- 5:05Speaker 2: week or something, you know. But in general, most patients
- 5:09Speaker 2: are more straightforward than than you would expect. I guess
- 5:14Speaker 2: for lack of a better phrase. Like again, when someone
- 5:17Speaker 2: thinks of want something like, holy crapest patient is you
- 5:22Speaker 2: know injecting drugs? Oh man? That means there, you know,
- 5:25Speaker 2: must be having all these other conditions, you know, HIV, hepatitis,
- 5:31Speaker 2: you know, And then what if I do something wrong
- 5:33Speaker 2: and the overdose and die and I was the last
- 5:35Speaker 2: provider you saw them, and I didn't have time to
- 5:37Speaker 2: do full evaluation, I didn't document anything. Am I going
- 5:39Speaker 2: to be a fault here kind of deal? So that
- 5:41Speaker 2: that prevents a lot of patients from being seen quickly.
- 5:46Speaker 1: And it really is so much easier than.
- 5:48Speaker 2: That, right, Yeah, for the majority of patients, you know,
- 5:51Speaker 2: they're they're human being. You know, they have lives, and
- 5:54Speaker 2: you know they they just want to get the help,
- 5:56Speaker 2: and oftentimes they don't get the help because of the
- 5:59Speaker 2: lack of access. So I'm just trying to help that
- 6:02Speaker 2: a little bit.
- 6:03Speaker 1: Well. And I think that's why it's important as as
- 6:07Speaker 1: a field to move away from the vernacular of medication
- 6:12Speaker 1: assistant treatment and go towards medication for opioid use disorder,
- 6:19Speaker 1: because we're Tait right, it's were like taking the importance
- 6:23Speaker 1: off of the how am I saying, how am I
- 6:29Speaker 1: saying that we're instead of you know, instead of medication
- 6:32Speaker 1: assisting in the treatment, meaning that there's this bigger picture happening,
- 6:37Speaker 1: We're just simply saying the medication is the treatment, you know,
- 6:42Speaker 1: And that's hugely important. And I think that's where the
- 6:48Speaker 1: things you're talking about is where we actually see that
- 6:50Speaker 1: come into effect. You know, I say it all the time.
- 6:54Speaker 1: It's like people just want their damn medication, Like they
- 6:57Speaker 1: just want the meds that are working for them, you know, Like, yes,
- 7:01Speaker 1: there are there are anomalies, there are extreme cases, there
- 7:06Speaker 1: can be patients with complications, yes, one hundred percent, But
- 7:10Speaker 1: for the most part, it just give the people their
- 7:15Speaker 1: damn meds, you know, Like they just want the meds
- 7:17Speaker 1: and they want to go about their life. They don't
- 7:19Speaker 1: want to talk about addiction and savoxone, and they don't
- 7:24Speaker 1: want to hear from their off the treatment office every day,
- 7:28Speaker 1: and they you know what I mean, they want it
- 7:30Speaker 1: to be like again, as least invasive as possible. You know,
- 7:34Speaker 1: they have families and jobs and lives and hobbies and
- 7:40Speaker 1: you know, and so I think again, going from the
- 7:44Speaker 1: m a T to the MOUD is really important in that,
- 7:50Speaker 1: But I did have a question about what you were
- 7:52Speaker 1: just saying. So if someone works for a hospital system,
- 7:56Speaker 1: let's say, I mean who who is dictating or how
- 8:01Speaker 1: has that decided what type of assessment you need to do. So,
- 8:05Speaker 1: like when you were just saying, you kind of, you know,
- 8:08Speaker 1: instead of asking what their substance use has been for
- 8:10Speaker 1: the last five years, you're focusing on the last week.
- 8:15Speaker 1: You're picking and choosing what's important in that moment and
- 8:18Speaker 1: what can be pushed off to later appointments, Like who,
- 8:21Speaker 1: how does that work for you? Guys in a large
- 8:24Speaker 1: system like that.
- 8:26Speaker 2: It's really up to the provider, the comfort level of
- 8:28Speaker 2: the provider. Because I've been doing this for at least
- 8:32Speaker 2: six years now, I have that experience of background where
- 8:35Speaker 2: I can just hone in on them more important things. Okay,
- 8:40Speaker 2: but would you have a lot of flexibility in terms
- 8:43Speaker 2: of how much medication we've prescribe aut as time, when
- 8:47Speaker 2: to fit in new patients, and when to see them back.
- 8:50Speaker 2: I think our only limbits are I just don't do
- 8:57Speaker 2: any super latant you know, like prescribe like like super
- 9:02Speaker 2: over over deer pagnoses like's you know, normal people peper
- 9:05Speaker 2: norphene sixteen to twenty four million grams per day. I mean,
- 9:09Speaker 2: if you prescribe like fifty six milligram or something like
- 9:11Speaker 2: that might look a little bit weird, you know, but
- 9:13Speaker 2: we have a lot of flexibility. I think a lot
- 9:16Speaker 2: of the providers are just being down so much by
- 9:19Speaker 2: being burnt out because of you know, productivity is how
- 9:22Speaker 2: many patients you're seeing so and because of that, that's
- 9:29Speaker 2: why they're like, I don't want to see a new
- 9:30Speaker 2: patient because obviously a new patient takes more time, and
- 9:33Speaker 2: the general thought or stigma is that someone who abuses
- 9:39Speaker 2: substances it's going to be much more complex and therefore
- 9:42Speaker 2: it takes time time. If you see one patient you
- 9:45Speaker 2: could have seen two or three, that reduces productivity. The
- 9:49Speaker 2: higher up will frown at you, right, So that's kind
- 9:52Speaker 2: of yeah.
- 9:52Speaker 1: I'm really hoping, and I've been talking about this with
- 9:56Speaker 1: some other colleagues, that we can start some sort of
- 10:00Speaker 1: of statewide educating on these topics with primary care physicians
- 10:08Speaker 1: all over the state, you know, hospital systems, private practice,
- 10:14Speaker 1: and you know, just help kind of hold their hand
- 10:18Speaker 1: and guide physicians who maybe haven't done a whole lot
- 10:21Speaker 1: of peopen rphine prescribing. I'm just waiting for the right
- 10:25Speaker 1: grant to come along. That's like, hey, we want to
- 10:27Speaker 1: pay you to go travel around the state and educate
- 10:30Speaker 1: these providers, you know, because I think, I guess it
- 10:34Speaker 1: would have to come from some level of authority, right,
- 10:38Speaker 1: you can't just be like this this guy from some
- 10:41Speaker 1: syringe program like it has to you know, it has
- 10:43Speaker 1: to be some like almost like a state authorized person
- 10:48Speaker 1: maybe for the physician to for it to carry any weight,
- 10:51Speaker 1: you know.
- 10:52Speaker 2: I wonder about that. Well, so I you know, when
- 10:56Speaker 2: I so there, I don't even have the ECO program.
- 10:59Speaker 2: I forget when stood for. But I I learned how
- 11:02Speaker 2: to prescribe proper norpheine through like a virtual training program.
- 11:06Speaker 2: So I was at the University of South sorry, University
- 11:09Speaker 2: of North Carolina, and so they had their own you know,
- 11:12Speaker 2: psychiatry clinic and their their addiction clinic. I was working
- 11:15Speaker 2: at a community house center, and they would help kind
- 11:18Speaker 2: of guide us during the preliminary stages of puper norphine prescription.
- 11:26Speaker 2: I think they got a grant to do it, but
- 11:27Speaker 2: I don't think you have to have any kind of
- 11:31Speaker 2: like license or like I guess good to have credential
- 11:36Speaker 2: because you know, you ideally would prefer that you're getting
- 11:38Speaker 2: taught from someone who knows what they're talking about, right,
- 11:41Speaker 2: But I don't think you need anything except you know,
- 11:43Speaker 2: time and someone was dedicated. So theoretically someone like like
- 11:49Speaker 2: the LGWDDING for example, with as the time could lead
- 11:54Speaker 2: one of those training sessions. While I have experience in
- 11:57Speaker 2: addition medicine, I'm not certified, so directly I could perscribe.
- 12:02Speaker 2: I could share my experience with them as a prima
- 12:04Speaker 2: care provider, which might be a little bit easier than
- 12:09Speaker 2: to have someone from addition medicine as well. But maybe
- 12:12Speaker 2: having someone from addition medicine and like a prima care
- 12:15Speaker 2: provider would kind of give them more of a diversified experiment.
- 12:19Speaker 1: Yeah, experience, whatever it is. You would just you know,
- 12:22Speaker 1: you'd want to like when I when I dream about
- 12:26Speaker 1: these these projects, like, yeah, you'd have you just want
- 12:31Speaker 1: to make sure that it's being taken seriously and that
- 12:35Speaker 1: the the providers are trusting of the information that you're
- 12:39Speaker 1: giving them, and that it's absolving of any concerns or
- 12:45Speaker 1: fears they may have, you know, you know, just that
- 12:48Speaker 1: it's coming from a trusted, authorized source. I guess, but
- 12:53Speaker 1: whether that whether that has to be some state agency,
- 12:56Speaker 1: I don't know, maybe just some some qualified practitioners of sorts.
- 13:02Speaker 1: But but I would love to you know, I would
- 13:05Speaker 1: love to see something like that. And I'm sure there's
- 13:06Speaker 1: a little maybe little examples of that happening. But I.
- 13:12Speaker 2: Think at the end of the day, it comes back
- 13:14Speaker 2: to whether not the prescribed the provider is willing to
- 13:18Speaker 2: prescribe it.
- 13:18Speaker 1: Right.
- 13:19Speaker 2: You can have all these training sessions and they are
- 13:22Speaker 2: part of the provider going back a little bit too,
- 13:24Speaker 2: like you know, being burnt out and productivities and so forth.
- 13:27Speaker 2: They can always say like I'm not going to do
- 13:29Speaker 2: this because the patients are more complicated. For example, about
- 13:33Speaker 2: two years ago, the University of Pittsburgh, I wanted to say,
- 13:38Speaker 2: I wanted to partner with us too as a research
- 13:43Speaker 2: project to give us a counselor and you know, to
- 13:47Speaker 2: help train the office to prescribe peper norphine. And they
- 13:51Speaker 2: needed two sites, my my clinic and a family medicine site.
- 13:55Speaker 2: My clinic was, you know, all in because I've been
- 13:57Speaker 2: prescribing d But the other clinic they were like, you know,
- 14:00Speaker 2: this seems like a lot of work. You know, we
- 14:03Speaker 2: don't know how to deal with his patients, so they
- 14:05Speaker 2: opped it out. Yeah, and then because of that, we're like,
- 14:08Speaker 2: we couldn't participate. So there are training programs, but I
- 14:11Speaker 2: think we just gotta beat the providers in the head
- 14:13Speaker 2: and we're like, you stop being stupid. I always like
- 14:17Speaker 2: this number. So, you know, whenever you have a heart
- 14:20Speaker 2: attack patients, you know, the doctors give you a cluster
- 14:26Speaker 2: of medicine like you know, a torrestein or libatoire or
- 14:29Speaker 2: a versus stein, which is like crush store. But the
- 14:33Speaker 2: number needed to treat, the number of patients needed to
- 14:35Speaker 2: treat with that medicine to prevent another heart attack is
- 14:38Speaker 2: around eighty two hundred people. The number of patients needed
- 14:41Speaker 2: to treat to prevent an overdose from people norphine people
- 14:44Speaker 2: norphane is just two.
- 14:46Speaker 1: So what can you explain that more? I don't understand.
- 14:48Speaker 1: What do you mean the number? Yeah?
- 14:50Speaker 2: So so the number needed to treat is a concept.
- 14:52Speaker 2: Where as so the medicine itself, like it doesn't you
- 15:00Speaker 2: have to treat a certain number of people to get
- 15:02Speaker 2: an expected outcome Because medicines they're not one hundred percent right,
- 15:08Speaker 2: they might work, you know, ten twenty percent. Right, So,
- 15:12Speaker 2: because of how effective a cluster medicine is or how
- 15:15Speaker 2: ineffective it is, you have to treat about eighty people
- 15:19Speaker 2: to get that desire outcome of preventing another heart attack.
- 15:22Speaker 1: That sounds really not great.
- 15:23Speaker 2: Not great, right, good freaking But every freaking person after
- 15:27Speaker 2: heart attack is on a cluster medicine because even though
- 15:29Speaker 2: eighty sounds like a pretty bad number, it's actually pretty good. Oh.
- 15:33Speaker 2: In terms of medicine, however, the like I said, the
- 15:36Speaker 2: number need to treat to prevent an overdose with people
- 15:38Speaker 2: norphreens two, meaning if you prescribe people into two people
- 15:42Speaker 2: who are helping prevent one of them from overdosing. So
- 15:47Speaker 2: if doctors really care about patients and their if their
- 15:50Speaker 2: goal is to help patients, this is the biggest difference
- 15:54Speaker 2: you can make. And that's basically how I became a
- 15:57Speaker 2: beeper nor for a prescriber because one day this high guy,
- 16:00Speaker 2: this guy like in the University of North Carolina, I
- 16:02Speaker 2: was like, Uh, this is a really high need area
- 16:05Speaker 2: and patients' need help, and you know, being the sucker,
- 16:08Speaker 2: I was like, hey, sure, sign me up.
- 16:09Speaker 1: Yeah.
- 16:10Speaker 2: And I also liked having the X on my license
- 16:12Speaker 2: because it looks like X men. You know, it looks cool.
- 16:15Speaker 2: But yeah, I think providers just need to like stop
- 16:19Speaker 2: being whisss and see what they're supposed to be doing.
- 16:23Speaker 1: So wait, wait, bring me back to that. So you're
- 16:25Speaker 1: in this was in residency.
- 16:27Speaker 2: I was at a community house center and there was
- 16:30Speaker 2: this researcher at the University of North Carolina that we're
- 16:32Speaker 2: still shared with, and he just turns out a massive
- 16:35Speaker 2: emailt like, hey, the obioy death over and overdose death.
- 16:39Speaker 2: There are the numbers on the rise. There's this medicine
- 16:42Speaker 2: called people norpheine that can help people prevented, and there
- 16:45Speaker 2: aren't any enough prescriber. And I was like, you know what,
- 16:49Speaker 2: yeah that sounds cool. It's not like I can help.
- 16:51Speaker 1: Yeah, you know, I want this X.
- 16:54Speaker 2: Yeah. And then and yeah, you're like, and then your
- 16:57Speaker 2: prescription you write X.
- 16:58Speaker 1: Thing.
- 16:59Speaker 2: It looks pretty good.
- 17:00Speaker 1: It's pretty cool.
- 17:00Speaker 2: But but again, I don't know if people have realized that,
- 17:03Speaker 2: you know, like how big of an impactper norphine can
- 17:07Speaker 2: make compared to other medical stuff that we do.
- 17:11Speaker 1: You know, well, it's interesting. That's a great point because
- 17:14Speaker 1: I obviously am aware. I guess I'm you know, obviously
- 17:22Speaker 1: I'm an advocate for how great bupenorphine is, but not
- 17:27Speaker 1: compared to other medications. I don't know. I'm not a physician.
- 17:29Speaker 1: I don't know like that the cluster med thing with
- 17:33Speaker 1: the heart attacks, like I wouldn't know, you know, how
- 17:35Speaker 1: how how effective is bupen orphine compared to other types
- 17:38Speaker 1: of treatments and other types of medications, And so that's
- 17:41Speaker 1: a really amazing thing to know, A great point to make. Obviously,
- 17:48Speaker 1: we hear the number of you know, fifty percent reduced
- 17:51Speaker 1: risk and overdose that's changing. I think now I've heard
- 17:55Speaker 1: like eighty percent. But you know, so we hear these
- 18:00Speaker 1: great you know, we consider methodone the gold standard, right
- 18:04Speaker 1: deep and orphines kind of falling into that label as well.
- 18:08Speaker 1: So we know it's insanely or you know, greatly effective,
- 18:12Speaker 1: But but I haven't heard it put like that compared
- 18:15Speaker 1: to other treatments. Do you know any other other numbers
- 18:20Speaker 1: like that of other you know what I mean, like
- 18:22Speaker 1: the eighty eighty people.
- 18:26Speaker 2: So there's actually one. Yeah, there's actually a website called
- 18:29Speaker 2: the Number needed to treat Oh so, so so the
- 18:35Speaker 2: way that that number is calculated, it's just like so
- 18:38Speaker 2: you mentioned you know, beeper morphine reduces overdose by fifty percent,
- 18:42Speaker 2: so that's called the absolute risk reduction. So the number
- 18:45Speaker 2: need to treat this is basically one over the absolute
- 18:47Speaker 2: risk reduction, So one over one point five becomes two.
- 18:50Speaker 1: Okay, So like wow.
- 18:52Speaker 2: Yeah, so like I think the taking a customer medicine
- 18:54Speaker 2: might lower the risk of a heart attack by say
- 18:58Speaker 2: ten percent or something like that. So one divided by
- 19:01Speaker 2: zero point one is one hundred. That's that's how they
- 19:06Speaker 2: kind of calculated.
- 19:07Speaker 1: Awesome. I would love to hear more of those, Like what,
- 19:12Speaker 1: I don't know, what would one be.
- 19:13Speaker 2: Like aspirin, you know, yeah, or like.
- 19:19Speaker 1: What diseases would be would fall in that, like uh,
- 19:23Speaker 1: type two diabetes with insulin or so let's see your
- 19:30Speaker 1: high blood pressure with a certain.
- 19:32Speaker 2: Yeah, so that the number of people that have to
- 19:36Speaker 2: take an aspirin to prevent their first heart attack or
- 19:39Speaker 2: stroke is actually three hundred and thirty three.
- 19:43Speaker 1: So if so, if you gave three hundred and thirty
- 19:46Speaker 1: three people an aspirin at the time of their heart attack.
- 19:51Speaker 2: No, no, no, So you know how back nowadays, like they're like,
- 19:54Speaker 2: if you're a high risk, you take an aspirin. Yeah,
- 19:57Speaker 2: like take a means aspirin. So you have to give
- 20:01Speaker 2: three hundred three hundred people an aspirin to just pre
- 20:05Speaker 2: when one heart attack in one of them. So, you know,
- 20:09Speaker 2: aspirin are like, you know, so.
- 20:10Speaker 1: Common, right, yeah, So does that mean the other three
- 20:14Speaker 1: hundred and thirty two die.
- 20:15Speaker 2: No, the other so the other So heart attacks aren't fatal, right,
- 20:19Speaker 2: They're they're bad, but not of them are fatal.
- 20:20Speaker 1: Right, oh right, But so it just means the other
- 20:23Speaker 1: three hundred and thirty two had a heart attack.
- 20:25Speaker 2: Yes, oh no, no, I'm sorry to not have a heart attack.
- 20:29Speaker 2: The other three hundred, two hundred ninety nine people did
- 20:32Speaker 2: not have any benefit from that spirint.
- 20:34Speaker 1: Oh okay, yeah, okay, but.
- 20:38Speaker 2: I guess potentially, Yeah, I guess a heart attack.
- 20:40Speaker 1: Okay, No, but I know I see what you mean. Yeah,
- 20:43Speaker 1: well it makes me think of maybe we'll wrap it
- 20:47Speaker 1: up on like somewhat emotional note or something. I don't know,
- 20:49Speaker 1: but I remember years ago, I was pretty new in
- 20:54Speaker 1: the field, and so you know, yeah, maybe this is
- 20:59Speaker 1: like eight years ago. And so the stigma, the stigma
- 21:04Speaker 1: around buben orphine was greater than it much greater than
- 21:08Speaker 1: it is now, even though it's still it's still not great,
- 21:13Speaker 1: but it was worse back then, and especially among like
- 21:17Speaker 1: recovery communities, recovery circles like twelve step communities, you know
- 21:22Speaker 1: aa NA. Abstinence based treatment like that was still a
- 21:26Speaker 1: big thing right where there was this like very anti
- 21:29Speaker 1: m at anti bubin orphine. And so I remember I
- 21:37Speaker 1: had this client once who came she was on pupin
- 21:41Speaker 1: orphine and then I think she started using again, went
- 21:47Speaker 1: back to went went to inpatient treatment like thirty days
- 21:51Speaker 1: or sixty days god, and it was an abstinence based program,
- 21:55Speaker 1: so she was on no medication. She was successful, she
- 21:58Speaker 1: got out, and she would keep in touch with me
- 22:02Speaker 1: every once in a while she texted me or call
- 22:04Speaker 1: me as her former counselor, and she was doing great,
- 22:07Speaker 1: you know, she was sober, going to meetings, doing that
- 22:11Speaker 1: whole thing. But sometime later, a month or two later,
- 22:16Speaker 1: she was really struggling with cravings, opioid cravings. And so
- 22:21Speaker 1: she would call and we would talk about that, and
- 22:23Speaker 1: we would we would you know, touch all the bases
- 22:28Speaker 1: of you know, therapy and counseling and meetings and social
- 22:31Speaker 1: supports and family and exercise and you know, like you know,
- 22:37Speaker 1: all the therapeutic categories of like health and well being, and
- 22:45Speaker 1: despite that work, she really continued to struggle with cravings.
- 22:49Speaker 1: So she came to me one day with this idea
- 22:53Speaker 1: of getting back on pup and orphine, which at that
- 22:56Speaker 1: time it's funny how things have changed now, but at
- 22:58Speaker 1: that time was seen as something extremely controversial because here
- 23:03Speaker 1: is someone who is not on opioids. Are they are
- 23:09Speaker 1: no longer opioid dependent, yet they're struggling with opioid cravings.
- 23:15Speaker 1: And so the idea of putting that individual back on
- 23:18Speaker 1: something like pep and orphine was really you know, unsure,
- 23:23Speaker 1: like people didn't know like is that okay? Can you
- 23:25Speaker 1: do that? Is that ethical? You know? It was just
- 23:30Speaker 1: very controversial, and so especially like I said, among the
- 23:33Speaker 1: recovery community, it was this very like, you know, that
- 23:37Speaker 1: would be crazy to do that. That's how I was perceived.
- 23:40Speaker 1: And I remember having these discussions. It wasn't just like
- 23:43Speaker 1: a spontaneous decision or a spontaneous question from the client.
- 23:51Speaker 1: You know, this was something we had talked about a
- 23:53Speaker 1: couple of times, and I remember having this thought that
- 23:58Speaker 1: what do I say, God forbid that person has a
- 24:03Speaker 1: reoccurrence of use and relapses, I'm sorry, and overdoses. How
- 24:09Speaker 1: would I respond to the family. This was just in
- 24:14Speaker 1: my head, probably driving in my car one day, but
- 24:16Speaker 1: I remember thinking, like, hypothetically, if this were to happen,
- 24:19Speaker 1: how would I respond to the family, knowing that there's
- 24:23Speaker 1: a medication out there that could have given this individual
- 24:27Speaker 1: a fifty percent greater chance at staying alive, you know.
- 24:31Speaker 1: And I just remember thinking that, having that epiphany, you know.
- 24:37Speaker 1: And ultimately we did that, We gave her the medication,
- 24:41Speaker 1: she got back on bupen orphine, and and that's the
- 24:46Speaker 1: decision we made with the treatment team. And and you know,
- 24:51Speaker 1: having spoken to her in years, but in the moment,
- 24:53Speaker 1: you know, in those days, she did not overdose, she
- 24:56Speaker 1: did not have a recurrence abuse, there was no relapse.
- 24:59Speaker 1: Everything worked out. But I don't know, that's just you know,
- 25:03Speaker 1: you talking about that just for you know the efficacy
- 25:06Speaker 1: of buben orphine and how underutilized it is and how
- 25:10Speaker 1: extremely effective it can be for some people. When you're
- 25:14Speaker 1: talking about the risk being death, it seems like a
- 25:20Speaker 1: no brainer, like it should be more utilized, it should
- 25:24Speaker 1: be more available, it should be less questioned, less restrictive,
- 25:29Speaker 1: like like again, getting back to my Maybe we'll title
- 25:32Speaker 1: this episode give people their damn Medication, because I just
- 25:39Speaker 1: you know, I don't know.
- 25:39Speaker 2: Man.
- 25:40Speaker 1: For me, that was a powerful moment, like I.
- 25:42Speaker 2: Think we need to follow the evidence and not so
- 25:45Speaker 2: much emotions. And during this time, you know, like you know,
- 25:48Speaker 2: like yeah, a lot of just follow damn evidence, you know,
- 25:51Speaker 2: like you know, service services, services, program work, nor works, medicine.
- 25:58Speaker 2: You know. Thanks for listening to the Needle and the Narrative,
- 26:03Speaker 2: a podcast by Challenges, Inc.
- 26:05Speaker 1: Sc Shout out to the Counter Narrative Project for making
- 26:08Speaker 1: this series possible and for their ongoing work.
- 26:11Speaker 2: To uplift marginalized voices and challenge dominant narratives and public health.
- 26:15Speaker 1: If you liked this episode, be sure to subscribe, share,
- 26:18Speaker 1: and follow us from more conversations on the intersections of
- 26:22Speaker 1: harm reduction, HIV and community.
- 26:24Speaker 2: Until next time, stay safe, take care of each other,
- 26:27Speaker 2: and keep challenging the narrative.